MicroStockProfit.com announces an investment report featuring Jazz Pharmaceuticals Inc.The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.ent "JAZZ recently announced financial results for the second quarter ended June 30, 2010, and updated financial guidance for 2010. The Company's updated financial guidance reflects higher expected sales of XYREM(R) (sodium oxybate) and the effects of recent financing activities. Total revenues for the quarter ended June 30, 2010, were $40.5 million, compared to $37.3 million for the quarter ended June 30, 2009. Total revenues included net product sales, royalties and contract revenues.
"JAZZ recently announced that it has prepaid the remaining $63.5 million principal amount of its 15% senior secured notes. The prepayment was made using a combination of borrowings under a new term loan and revolving credit facility with Silicon Valley Bank that closed on June 30, 2010, and cash on hand. The $50 million term loan will amortize in twelve equal quarterly installments of $4.2 million."
No comments:
Post a Comment